Chris Mix

Company: Vera Therapeutics

Job title: Executive Vice President – Clinical Development

Seminars:

10:30 AM Atacicept in IgAN: Evaluating Safety and Efficacy for High-Risk Patients with Persistent Proteinuria 10:30 am

Running multinational, randomized, double-blind, placebo-controlled Phase 2b study assessing atacicept in IgAN patients Focussing in on high-risk IgAN patients who continue to experience persistent proteinuria, indicating ongoing disease progression Evaluating the safety profile and efficacy of atacicept in managing disease progression in this specific patient groupRead more

day: Conference Day 2

3:30 PM Panel Discussion: Lessons Learnt from Successful Clinical Trials in IgAN & C3G to Inform Successful Clinical Design & Development in Wider Rare & Genetic Kidney Diseases 3:30 pm

Advancing understanding of disease pathophysiology and biomarker identification to guide the development of therapies with distinguished mechanism of actions Discussing suitable design of placebo arm and standard of care for rare diseases Examining the importance of integrating patient-reported outcomes, quality of like measures and comparative effectiveness research early in clinical development to demonstrate meaningful differentiationRead more

day: Conference Day 1